生物科技公司Tarsus Pharmaceuticals(TARS)股价今日盘中大跌7.77%,引发了市场的广泛关注。这一大跌引发了投资者对该公司前景的担忧。
导致股价大跌的主要原因是,Tarsus Pharmaceuticals刚刚公布了截至2024年12月31日的第四季度财报,季度亏损扩大至2311万美元,相比去年同期的1.31美元收益,出现了转亏。
尽管本季度营收同比大幅增长407.9%至6641万美元,略高于华尔街预期,但公司每股亏损60美分,也超出了分析师预期的每股亏损74美分。该公司股价在过去三个月下跌了17.8%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.